3 symptoms (reflux, disrupted swallowing, nausea/vomiting, belly pain, gas /bloating /flatulence, diarrhea, constipation, and fecal incontinence). The objective of this study was to evaluate the construct validity of the PROMIS-GI bank in SSc.
Methods: 167 patients with SSc were administered the PROMIS GI bank and the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Scale (GIT 2.0) instrument. GIT 2.0 is a multi-item instrument that measures SSc-associated GI symptoms. Product-moment correlations and a multitrait-multimethod analysis of the PROMIS GI scales with the GIT 2.0 symptom scales were used to evaluate convergent and discriminant validity.
Results:
Patients with SSc GI involvement had PROMIS GI scale scores 0.2-0.7 SD worse than US population. Correlations among scales measuring the same domains for the PROMIS GI and GIT 2.0 measures were large, ranging from 0.61 to 0.87 (average r = 0.77). The average correlation between different symptom scales was 0.22, supporting discriminant validity.
Conclusion:
This study provides support for the construct validity of the PROMIS GI scales in SSc. Future research is needed to assess the responsiveness to change of these scales in patients with SSc.
Significance and innovations

Patient reported outcomes (PRO) play an important role in clinical
practice. They help to assess the disease burden and guide treatment.
2. PROMIS instruments are more precise than existing legacy measures.
INTRODUCTION
Patient-reported outcomes (PROs) are widely used in research and they are playing an increasingly important role in clinical practice (1) . In a clinical practice, PROs can be administered to identify presence/ absence of symptoms or assess symptoms severity which can assist in clinical decision making (2) . Unlike the 5 traditional measures of disease burden (direct and indirect expenditures of a disease), PRO instruments document the burden of disease in terms of impact on daily functioning and well-being, or health-related quality of life (HRQOL) (3).
Gastrointestinal tract (GI) involvement occurs in approximately 90% of patients with systemic sclerosis (SSc) (4, 5) and is associated with decline in HRQOL (6, 7) . The University of California, Los Angeles Scleroderma Clinical Trials Consortium Gastrointestinal Scale (UCLA SCTC GIT 2.0; GIT 2.0 from hereon) is a multi-item instrument that measures GI symptoms and their impact on HRQOL.
Support for the reliability and validity (including responsiveness to change) of the GIT 2.0 was found in different observational cohorts (8) (9) (10) (11) . It is considered the "legacy" instrument to assess GI involvement in patients with SSc (2).
The National Institutes of Health (NIH)-funded the Patient-Reported Outcomes Measurement Information System (PROMIS®) Roadmap to develop, evaluate, and standardize item banks to measure patient-reported outcomes across patients with different medical conditions and in the US general population (12, 13) . PROMIS GI Symptom item banks that assess 8 GI domains were recently developed (14, 15) . The goal of PROMIS is to develop reliable and valid item banks using item response theory (IRT) that can be administered in a variety of formats including short forms and computerized adaptive tests (12, 16, 17) . PROMIS has several advantages over the traditional instruments. First, a consistent qualitative process is employed with detailed systematic review, focus 6 groups, cognitive interviews, and translatability for each item bank. Second, PROMIS static items produce more reliable information than existing measures such as the SF-36 physical functioning-10 and health assessment questionnairedisability index (18) .
The goal of this study was to evaluate the construct validity of the PROMIS GI Symptom scales.
MATERIALS AND METHODS
Patient-reported outcome measures
NIH PROMIS GI Symptom item bank
The GI Symptom item banks were developed using the standard PROMIS qualitative and quantitative methodology (19) . Briefly, the qualitative aim was achieved through completion of a systematic review of the literature to identify extant GI PRO items followed by a comprehensive review and evaluation of these items (15) . The individual items from existing instruments were grouped based on different symptoms. This was complemented by focus group discussions of patients with GI conditions to evaluate their symptoms. New items were developed based on extant items and input from the focus group participants followed by fine tuning of item wording based on cognitive interviews with GI patients. The items were administered to 865 patients with different GI The final PROMIS GI Symptom instrument (15) has 60 items and assesses 8 domains: gastroesophageal reflux (13 items), disrupted swallowing (7 items), diarrhea (5 items), bowel incontinence/soilage (4 items), nausea and vomiting (4 items), constipation (9 items), belly pain (6 items), and gas /bloating /flatulence (12 items). All scales were calibrated using the two-parameter item response theory (IRT) graded response model and scored on a T-score metric with a mean of 50 and SD of 10 in the U.S. general population. A higher score denotes more GI symptoms. The recall period for PROMIS GI Symptom items is 1-week.
GIT 2.0
The GIT 2.0 was developed to assess presence / absence and severity of gastrointestinal involvement and the consequent impairment in social and emotional well-being in patients with SSc (11) . Previous work has provided support for the reliability and validity of the GIT 2.0 scales (11, 20) . The GIT 2.0 scales were found to be sensitive to the presence of abnormalities on structural / motility testing and can be routinely used as initial screening test in clinical practice (8) . It is the "legacy" PRO measure to assess the severity of GI 8 involvement and its impact on HRQOL in patients with SSc. The GIT 2.0 has 34 items; the 7 multi-item scales include reflux (8 items), distention/bloating (4 items), diarrhea (2 items), fecal soilage (1 item), constipation (4 items), emotional well-being (9 items), and social functioning (6 items 
Statistical analysis
Descriptive statistics are presented as mean (standard deviations) for continuous variables and percentages for categorical variables. In addition to mean scores and standard deviations (SD), ranges, and percentages of respondents scoring the minimum and maximum possible scores were calculated to evaluate scale score distributions for the PROMIS GI Symptom and GIT 2.0 scales. Internal consistency reliability for all scales was estimated using Cronbach's alpha and reliability for the GIT 2.0 total score was estimated using Mosier's formula. Reliability ≥ 0.70 was considered satisfactory for group comparisons (22) .
Convergent and discriminant validity are two components of construct validity. Convergent validity is supported when different methods of assessing the same construct (e.g. two measures of reflux) should be highly correlated. Pearson's product-moment correlations of the PROMIS GI Symptom scales with corresponding GIT 2.0 scales were used to assess convergent validity.
Discriminant validity is supported when measures of different constructs (e.g. diarrhea and constipation) do not correlate highly with each other. We conducted multitrait-multimethod Matrix (MTMM) analyses to evaluate convergent and discriminant validity (23) . We hypothesized that correlations among scales measuring the same construct would be significantly larger than other correlations (24) . A coefficient of ≥ 0.50 was considered large for current analysis.
RESULTS
The majority of participants were female (91%), Caucasian (54%), and highly educated (98% with some college degree); the mean age of the sample was 53 years (SD = 13; Table 1 ). 
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The average convergent validity correlation in the MTMM was 0.77 and the average off-diagonal correlation was 0.22 (Table 4) The PROMIS GI scales assess symptoms that can be used to assess the general population and patients with different GI disorders. In the current study, PROMIS GI Symptom scales were compared to the widely used GIT 2.0 to explore its construct validity in patients with SSc. Correlations between PROMIS GI scales and corresponding GIT 2.0 scales were large and correlations of responsiveness to change in a longitudinal study. In our study, PROMIS scales had lower percentage of patients in different scales who achieved minimum and maximum scores compared to GIT 2.0 suggesting that measurement precision may be better for PROMIS bank over a wide range compared to GIT 2.0. This will likely increase the ability to detect true change and to fulfill power and sample size requirements (30, 31) .
Our study has several strengths. First, it provides support for the PROMIS GI Symptom scales in patients with SSc. Next, it adds to the limited repertoire of psychometrically sound instruments to assess the GI burden of SSc. In clinical practice and trials, incorporation of either GIT 2.0 or PROMIS GI scales is appropriate. Third, PROMIS GI has advantage of separate scales for disrupted swallowing and nausea/ vomiting (applicable in SSc) and will have data available on same metric that allows comparison of prevalence/ severity of symptoms in patients with SSc with general population and other GI disorders such as inflammatory bowel disease and irritable bowel disorder. On the other hand, PROMIS GI scales require a computer to calculate the scores whereas GIT 2.0 can be scored in the office setting.
The study is not without limitations. First, the GIT 2.0 was one of the "legacy" instruments used during the development of GI Symptom item bank. Although there are other measures to assess GI involvement in SSc, none have been comprehensivly evaluated as GIT 2.0 (2). Second, the study population was quite 14 homogenous predominantly involving females (91%), mainly Caucasians and patients who were highly educated (63% with graduate degree). Larger studies in SSc and other GI disorders will need to be conducted to assess responsiveness to change of PROMIS GI item bank vs. other "legacy" instruments.
In conclusion, this study provides support for the construct validity of the PROMIS GI Symptom item scales in patients with SSc. These items are ready for use in clinical practice to assess the presence and severity of GI symptoms. 
